Skip to content

US · ANIK · MEDICAL - DEVICES

Anika Therapeutics, Inc. (ANIK) intrinsic value and stock valuation

$13.23as of 2026-11-21 · Mkt cap 256.82M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Anika Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ANIK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ANIK’s statements →

Anika Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Bedford, MA 01730 anika.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$112.8M-2.9% 5y CAGRd
20112025
Net income
-$-10.88M
20112025
Free cash flow
$4.36M-17.5% 5y CAGRd
20112025
Total equity
$143.5M-12% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$112.8M$119.9M$120.8M$113.8M$147.8M
Operating income-$-11.05M-$-5.1M$840K$3.67M$2.62M
Net income-$-10.88M-$-56.38M-$-82.67M-$-14.86M$4.13M
EPSd-$-758.72K-$-3.83M-$-5.64M-$-1.02M$282.3K
Operating cash flow$11.2M$5.4M-$-1.79M$4.41M$8.4M
Capital expenditure-$-6.83M-$-7.73M-$-5.43M-$-7.49M-$-5.14M
Free cash flow$4.36M-$-2.33M-$-7.21M-$-3.08M$3.25M
Total assets$190.3M$202.7M$270.6M$349.1M$347.5M
Total debt$26.3M$25.9M$27.7M$30.9M$21M
Net debt-$-31.23M-$-29.7M-$-41M-$-55.44M-$-73.43M
Total equity$143.5M$154M$212.3M$285.6M$287.1M
Cash and short-term investments$57.5M$55.6M$68.7M$86.3M$94.4M
Income statement
20252024202320222021
Revenue$112.8M$119.9M$120.8M$113.8M$147.8M
Cost of revenue$49M$43.9M$38.3M$40.6M$64.9M
Gross profit$63.8M$76M$82.5M$73.2M$82.9M
Research and development expenses$25.8M$25.5M$21.8M$18.3M$27.3M
Selling, general and administrative expenses$49.1M$55.6M$59.9M$51.2M$74.1M
Other expenses$0.00$0.00$0.00$0.00-$-21.09M
Operating expenses$74.9M$81.1M$81.7M$69.6M$80.3M
Cost and expenses$123.9M$125M$120M$110.2M$145.2M
Interest income$0.00—$2.31M$650K—
Interest expense$0.00—$0.00$0.00—
Depreciation and amortization$5.73M$8.12M$14.2M$14.5M$14.3M
Ebitda-$-3.58M$5.36M$17.4M$18.8M-$-4.16M
Operating income-$-11.05M-$-5.1M$840K$3.67M$2.62M
Total other income/expenses, net$1.74M$2.34M$2.31M$650K-$-190K
Income before tax-$-9.31M-$-2.76M$3.16M$4.32M$2.43M
Income tax expense$670K$6.06M$6.59M$2.12M-$-1.71M
Net income-$-10.88M-$-56.38M-$-82.67M-$-14.86M$4.13M
Weighted average shares outstanding$14.3M$14.7M$14.7M$14.6M$14.4M
Weighted average diluted shares outstanding$14.3M$14.7M$14.7M$14.6M$14.6M
Balance sheet
20252024202320222021
Cash and short-term investments$57.5M$55.6M$68.7M$86.3M$94.4M
Net receivables$23.7M$23.6M$26.4M$34.6M$29.8M
Inventory$18.8M$23.8M$24.4M$39.8M$36M
Total current assets$103.4M$113.7M$163.3M$169.6M$168.5M
Property, plant and equipment, net$66.3M$64.7M$65M$79M$68.6M
Goodwill and intangible assets$9.7M$9.62M$10.2M$81.9M$90.2M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$86.9M$89.1M$107.3M$179.6M$179M
Total assets$190.3M$202.7M$270.6M$349.1M$347.5M
Accounts payable$6.04M$5.62M$6.19M$9.07M$7.63M
Short-term debt$2.05M$1.92M$1.83M$2.07M$1.71M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$21.9M$23.3M$31.1M$27.9M$29.8M
Long-term debt$24.2M$24M$25.9M$28.8M$19.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$24.9M$25.5M$27.3M$35.7M$30.7M
Capital lease obligations$2.05M$25.9M$27.7M$30.9M$21M
Total liabilities$46.8M$48.8M$58.4M$63.6M$60.5M
Common stock$140K$140K$150K$150K$140K
Retained earnings$60.8M$71.7M$128.1M$210.7M$225.6M
Accumulated other comprehensive income (loss)-$-4.96M-$-6.78M-$-5.94M-$-6.44M-$-5.72M
Total equity$143.5M$154M$212.3M$285.6M$287.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$26.3M$25.9M$27.7M$30.9M$21M
Net debt-$-31.23M-$-29.7M-$-41M-$-55.44M-$-73.43M
Cash flow statement
20252024202320222021
Net income-$-10.88M-$-56.38M-$-82.67M-$-14.86M$4.13M
Depreciation and amortization$5.73M$8.12M$14.2M$14.5M$14.3M
Stock-based compensation$10.1M$13.1M$15.2M$14.3M$11.1M
Change in working capital-$-820K-$-13.09M-$-12.12M-$-11.82M-$-14.72M
Accounts receivable$410K$3.37M-$-1.3M-$-5.63M-$-6.22M
Inventory$30K-$-9.42M-$-11.4M-$-6.87M-$-6.62M
Accounts payable$40K-$-2.51M-$-10K$1.97M-$-1.1M
Net cash provided by operating activities$11.2M$5.4M-$-1.79M$4.41M$8.4M
Investments in property, plant and equipment-$-6.83M-$-7.73M-$-5.43M-$-7.49M-$-5.14M
Acquisitions, net$8.99M$0.00$0.00$0.00-$-480K
Net cash used for investing activities-$-400K-$-8.33M-$-5.43M-$-7.49M-$-3.12M
Common stock issued$500K$0.00$0.00$680K$1.13M
Common stock repurchased-$-9.48M-$-10.91M-$-5M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-10.55M-$-12.73M-$-6.32M-$-4.85M-$-6.78M
Net change in cash$320K-$-15.71M-$-13.46M-$-8.06M-$-1.43M
Cash at end of period$57.5M$57.2M$72.9M$86.3M$94.4M
Operating cash flow$11.2M$5.4M-$-1.79M$4.41M$8.4M
Capital expenditure-$-6.83M-$-7.73M-$-5.43M-$-7.49M-$-5.14M
Free cash flow$4.36M-$-2.33M-$-7.21M-$-3.08M$3.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Anika Therapeutics, Inc.

        Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

        CEO
        Stephen D. Griffin
        Employees
        235
        Beta
        0.19

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Anika Therapeutics, Inc. (ANIK)?

        Anika Therapeutics, Inc. (ANIK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ANIK undervalued?

        ANIK trades at a price of $13.23 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.